147 related articles for article (PubMed ID: 25131863)
21. New and emerging agents for the treatment of castration-resistant prostate cancer.
Higano CS; Crawford ED
Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
[TBL] [Abstract][Full Text] [Related]
22. Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
Climent MÁ; León-Mateos L; González Del Alba A; Pérez-Valderrama B; Méndez-Vidal MJ; Mellado B; Arranz JÁ; Sánchez-Hernández A; Cassinello J; Olmos D; Carles J
Crit Rev Oncol Hematol; 2015 Nov; 96(2):308-18. PubMed ID: 26100652
[TBL] [Abstract][Full Text] [Related]
23. Emerging drugs for prostate cancer.
Chung PH; Gayed BA; Thoreson GR; Raj GV
Expert Opin Emerg Drugs; 2013 Dec; 18(4):533-50. PubMed ID: 24274615
[TBL] [Abstract][Full Text] [Related]
24. Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
Aragon-Ching JB
Future Oncol; 2014 Feb; 10(3):329-32. PubMed ID: 24559439
[No Abstract] [Full Text] [Related]
25. A urologic oncology roundtable discussion: the role of disease monitoring in treatment decision-making for patients with metastatic castration-resistant prostate cancer.
Shore ND; Concepcion R; Barocas DA
Hosp Pract (1995); 2013; 41(4):78-80. PubMed ID: 24145592
[TBL] [Abstract][Full Text] [Related]
26. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
27. A urologic oncology roundtable discussion: how to choose among the available therapies for the treatment of castration-resistant prostate cancer.
Ryan C; Shore ND; Concepcion R
Postgrad Med; 2013 Nov; 125(6):114-6. PubMed ID: 24200767
[TBL] [Abstract][Full Text] [Related]
28. A urologic oncology roundtable discussion: issues to consider in choosing treatment for metastatic castration-resistant prostate cancer.
Taplin ME; Berry WR; Casey AM; Aslo A
Hosp Pract (1995); 2013; 41(4):81-2. PubMed ID: 24145593
[TBL] [Abstract][Full Text] [Related]
29. [Advances in the studies of androgen metabolism and de novo androgen synthesis in castration resistant prostate cancer].
Wang B; Wu KJ; He DL
Zhonghua Nan Ke Xue; 2013 Aug; 19(8):736-41. PubMed ID: 24010211
[TBL] [Abstract][Full Text] [Related]
30. Current and emerging treatments in the management of castration-resistant prostate cancer.
Shapiro D; Tareen B
Expert Rev Anticancer Ther; 2012 Jul; 12(7):951-64. PubMed ID: 22845410
[TBL] [Abstract][Full Text] [Related]
31. Clinical phenotypes of castration-resistant prostate cancer.
Zhang T; Armstrong AJ
Clin Adv Hematol Oncol; 2013 Nov; 11(11):707-18. PubMed ID: 24896544
[TBL] [Abstract][Full Text] [Related]
32. Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel.
Arsov C; Winter C; Rabenalt R; Albers P
Urol Oncol; 2012; 30(6):762-71. PubMed ID: 20884252
[TBL] [Abstract][Full Text] [Related]
33. Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma.
Pinto A
Cancer Chemother Pharmacol; 2014 Feb; 73(2):219-22. PubMed ID: 24202668
[TBL] [Abstract][Full Text] [Related]
34. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
35. Abiraterone acetate in castration-resistant prostate cancer.
Iacovelli R; Palazzo A; Procopio G; Gazzaniga P; Cortesi E
Anticancer Drugs; 2012 Mar; 23(3):247-54. PubMed ID: 22123334
[TBL] [Abstract][Full Text] [Related]
36. New developments in castrate-resistant prostate cancer.
Shore N; Mason M; de Reijke TM
BJU Int; 2012 Jun; 109 Suppl 6():22-32. PubMed ID: 22672122
[TBL] [Abstract][Full Text] [Related]
37. Molecular landscape of prostate cancer: implications for current clinical trials.
Khemlina G; Ikeda S; Kurzrock R
Cancer Treat Rev; 2015 Nov; 41(9):761-6. PubMed ID: 26210103
[TBL] [Abstract][Full Text] [Related]
38. Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer.
Dellis A; Papatsoris AG
Expert Opin Biol Ther; 2014 Jan; 14(1):7-10. PubMed ID: 24074253
[TBL] [Abstract][Full Text] [Related]
39. Update on castrate-resistant prostate cancer: 2010.
Lassi K; Dawson NA
Curr Opin Oncol; 2010 May; 22(3):263-7. PubMed ID: 20177381
[TBL] [Abstract][Full Text] [Related]
40. Metabolic and toxicological considerations of newly approved prostate cancer drugs.
Tsao CK; Liaw B; Yee T; Galsky MD; Oh WK
Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):835-46. PubMed ID: 23581700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
